肌肉受体激活剂作为精神分裂症的新疗法
Steven M Paul1, Samantha E Yohn2, Stephen K Brannan2
1Karuna Therapeutics, Boston, Massachusetts; Department of Psychiatry and Neurology, Washington University of St. Louis, St. Louis, Missouri.
新的研究探索了肌酸乙胆受体 (mAChR) 激动剂作为精神分裂症的新疗法,可能会比目前的多巴胺D2受体对抗剂提高疗效. 这种方法可以解决负面和认知症状,为患者提供新的希望.
科学领域:
- 神经科学是一个神经科学.
- 心理药理学 心理药理学
- 接受器药理学 接受器药理学
背景情况:
- 尽管已经有70年的药物开发,但精神分裂症的治疗仍然具有挑战性.
- 目前的抗精神病药物,主要是多巴胺D2受体对抗剂,对负面和认知症状的疗效有限.
- 需要新的治疗目标来改善治疗结果.
研究的目的:
- 调查肌酸乙胆受体 (mAChR) 激动剂作为精神分裂症新治疗策略的潜力.
- 探索针对特定的mAChRs的抗精神病类和前认知效应.
主要方法:
- 审查关于抗精神病药物开发和有效性的现有文献.
- 对肌肉酸乙胆受体 (mAChRs) 和它们在认知和精神疾病中的作用的研究分析.
- 检查与精神分裂症和阿尔茨海默病中的mAChR激动剂相关的临床试验结果.
主要成果:
- 双重M1/M4偏好的mAChR激动剂已经显示出类似抗精神病药物的效果和促认知性质.
- 最近的临床试验支持针对mAChRs治疗精神分裂症的有效性.
- 了解xanomeline的受体结合特性将为未来的药物设计提供信息.
结论:
- 肌肉酸乙胆受体 (mAChR) 激动剂代表了对精神分裂症的有前途的新疗法.
- 针对mAChRs可能会提供更广泛的疗效,包括改善负面和认知症状.
- 对mAChR药理学的进一步研究可以指导下一代抗精神病药物的开发.
更多相关视频
05:14Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
相关概念视频
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
